肝腎症候群治療市場規模、佔有率和成長分析：按療法、藥物類別、疾病、給藥途徑、分銷管道、最終用戶和地區分類－2026-2033年產業預測

2024 年全球肝腎症候群 (HRS) 治療市場價值為 3.124 億美元，預計從 2025 年的 3.3052 億美元成長到 2033 年的 5.189 億美元，預測期（2026-2033 年）的複合年成長率為 5.8%。

全球肝腎綜合症 (HRS) 治療市場涵蓋了針對進行性性肝病導致的腎衰竭的藥物、生物製藥和支持療法。 HRS 的高死亡率使得有效療法的迫切需求日益凸顯，市場正從傳統的血管收縮劑轉向創新的聯合治療，尤其是特利加壓素-白蛋白療法。這項轉變得益於成功的臨床試驗，推動了研發投入的增加和標準化醫院方案的採用。白蛋白療法與選擇性血管收縮劑合併應用，能夠有效解決 HRS 的潛在血流動力學失衡問題，從而增加了對這些療法的需求。此外，人工智慧正在革新治療研發，加速患者分層，提升個人化醫療水平，進而拓展治療選擇，改善市場環境，並推動市場成長。

全球肝腎綜合症治療市場的成長要素

慢性肝病盛行率的不斷上升顯著擴大了需要接受肝腎症候群治療的患者群體，迫使醫療機構尋求有效的治療方法。隨著越來越多的患者出現晚期肝功能障礙，腎臟併發症的發生率也在上升，導致專科治療的需求持續增加。這種日益成長的臨床需求促使製藥公司加強研發投入，最終推動了市場產品的多樣化。此外，人們對該疾病負擔的認知不斷提高，也影響了處方行為，並促使企業投資於創新治療方案，進一步加速了市場成長和擴張。

全球肝腎綜合症治療市場的限制因素

由於保險報銷範圍有限，全球肝腎綜合症治療市場面臨諸多限制因素，患者難以獲得昂貴的治療。當保險公司設定嚴格的合格標準或僅提供極低的報銷率時，醫療專業人員往往不願意開立這些昂貴的處方，而傾向於採用較保守的治療方案。這種經濟壓力不僅降低了治療的接受度，也阻礙了製藥公司投入大量資源拓展市場佔有率。因此，市場成長受到抑制，價格壓力和報銷的不確定性阻礙了創新療法的廣泛應用，並限制了整個治療領域的發展。

全球肝腎綜合症治療市場趨勢

全球肝腎綜合症治療市場正經歷著向精準醫療的顯著轉變，這從根本上改變了治療方法。臨床醫生擴大利用基因組分析和基於生物標記的策略，根據每位患者的個別需求量身定做治療方案，從而提高療效並最大限度地減少副作用。這項轉變促使製藥公司將重點放在開發伴隨診斷試劑盒的同時開發治療藥物。因此，生技公司與診斷試劑製造商之間的合作日益普遍，從而能夠實現個人化醫療模式，滿足全球不同醫療體系中以價值為導向的支付方的期望。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球肝腎綜合症治療市場規模：依治療類型分類

• 血管收縮劑療法
• 白蛋白療法
• 聯合治療（血管收縮劑+白蛋白）
• 腎臟替代療法（透析）
• 肝臟移植
• 其他

全球肝腎綜合症治療藥物市場規模：依藥物類別分類

• 血管加壓素類似物
• α-腎上腺素促效劑
• 生長抑制素類似物
• 血漿容量轉移劑（白蛋白）
• 其他

全球肝腎綜合症治療市場規模：依疾病類型分類

• 1型肝腎症候群（HRS-AKI）
• 2型肝腎症候群（HRS-CKD/非AKI）

全球肝腎綜合症治療藥物市場規模：依給藥途徑分類

• 靜脈
• 皮下
• 口服

全球肝腎綜合症治療市場規模：按分銷管道分類

• 醫院藥房
• 零售藥房
• 網路藥房

全球肝腎綜合症治療市場規模：依最終用戶分類

• 醫院
• 專科診所
• 門診手術中心
• 其他

全球肝腎綜合症治療市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Mallinckrodt plc
• Grifols SA
• Orphan Therapeutics LLC
• Takeda Pharmaceutical Company Limited
• Sanofi SA
• Pfizer Inc
• Novartis AG
• Baxter International Inc
• CSL Behring LLC
• Octapharma AG
• Kedrion Biopharma
• Biotest AG
• LFB USA Inc
• Bio Product Laboratory Ltd
• China Biologic Products Holdings Inc
• Ferring Pharmaceuticals
• Biopas Laboratories
• Cumberland Pharmaceuticals Inc
• Melinta Therapeutics LLC
• Salix Pharmaceuticals Inc

結論與建議

Global Hepatorenal Syndrome Treatment Market size was valued at USD 312.4 Million in 2024 and is poised to grow from USD 330.52 Million in 2025 to USD 518.9 Million by 2033, growing at a CAGR of 5.8% during the forecast period (2026-2033).

The global market for hepatorenal syndrome (HRS) treatment encompasses pharmaceuticals, biologics, and supportive care aimed at renal failure resulting from advanced liver disease. High mortality rates associated with HRS create an urgent need for effective therapies, transitioning the market from traditional vasoconstrictor agents to innovative combination treatments, notably the terlipressin-albumin regimen. This shift has catalyzed increased R&D investment and the adoption of standardized hospital protocols based on clinical trial success. The growing use of albumin-based therapies combined with selective vasoconstrictors addresses the fundamental hemodynamic imbalances behind HRS, leading to heightened demand for these treatments. Additionally, AI is revolutionizing therapy development, enabling faster patient stratification and enhancing personalized care, thus widening the therapeutic landscape and creating momentum for market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hepatorenal Syndrome Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hepatorenal Syndrome Treatment Market Segments Analysis

Global hepatorenal syndrome treatment market is segmented by treatment type, drug class, disease type, route of administration, distribution channel, end user and region. Based on treatment type, the market is segmented into Vasoconstrictor Therapy, Albumin Therapy, Combination Therapy (Vasoconstrictors + Albumin), Renal Replacement Therapy (Dialysis), Liver Transplantation and Others. Based on drug class, the market is segmented into Vasopressin Analogues, Alpha-Adrenergic Agonists, Somatostatin Analogues, Plasma Volume Expanders (Albumin) and Others. Based on disease type, the market is segmented into Type 1 Hepatorenal Syndrome (HRS-AKI) and Type 2 Hepatorenal Syndrome (HRS-CKD/Non-AKI). Based on route of administration, the market is segmented into Intravenous, Subcutaneous and Oral. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on end user, the market is segmented into Hospitals, Specialty Clinics, Ambulatory Surgical Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hepatorenal Syndrome Treatment Market

The increasing incidence of chronic liver disease is significantly broadening the population in need of hepatorenal syndrome treatments, driving healthcare providers to pursue effective therapeutic options. As more patients experience advanced liver dysfunction, the occurrence of renal complications rises, resulting in a continuous demand for specialized interventions. This growing clinical need compels pharmaceutical companies to focus on research and development, ultimately contributing to a more diverse range of products in the market. Additionally, the rising awareness of the disease burden stimulates prescribing practices and boosts investments in innovative treatment solutions, further propelling market growth and expansion.

Restraints in the Global Hepatorenal Syndrome Treatment Market

The Global Hepatorenal Syndrome Treatment market faces significant restrictions due to limited reimbursement coverage policies, which hinder patient access to costly therapies. When insurance providers implement stringent eligibility criteria or offer minimal reimbursement rates, healthcare professionals are often reluctant to prescribe these expensive treatments, frequently resorting to more conservative management approaches. This financial challenge not only decreases treatment uptake but also discourages manufacturers from committing substantial resources to expand their presence in the market. As a result, market growth is stifled, with pricing pressures and reimbursement uncertainties hampering the broader adoption of innovative therapeutic options and constraining the development of the overall treatment landscape.

Market Trends of the Global Hepatorenal Syndrome Treatment Market

The Global Hepatorenal Syndrome Treatment market is witnessing a significant trend towards the integration of precision medicine, fundamentally transforming therapeutic approaches. Clinicians are increasingly employing genomic profiling and biomarker-driven strategies to tailor treatments to individual patient needs, enhancing efficacy and minimizing side effects. This shift is encouraging pharmaceutical companies to focus on developing companion diagnostics alongside their therapeutic offerings. As a result, collaborations between biotech firms and diagnostic companies are becoming more prevalent, leading to a personalized care model that meets the demands of evolving payer expectations for value-based outcomes across diverse healthcare systems globally.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Hepatorenal Syndrome Treatment Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Vasoconstrictor Therapy
• Albumin Therapy
• Combination Therapy (Vasoconstrictors + Albumin)
• Renal Replacement Therapy (Dialysis)
• Liver Transplantation
• Others

Global Hepatorenal Syndrome Treatment Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Vasopressin Analogues
• Alpha-Adrenergic Agonists
• Somatostatin Analogues
• Plasma Volume Expanders (Albumin)
• Others

Global Hepatorenal Syndrome Treatment Market Size by Disease Type & CAGR (2026-2033)

• Market Overview
• Type 1 Hepatorenal Syndrome (HRS-AKI)
• Type 2 Hepatorenal Syndrome (HRS-CKD/Non-AKI)

Global Hepatorenal Syndrome Treatment Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Intravenous
• Subcutaneous
• Oral

Global Hepatorenal Syndrome Treatment Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Hepatorenal Syndrome Treatment Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Others

Global Hepatorenal Syndrome Treatment Market Size & CAGR (2026-2033)

• North America (Treatment Type, Drug Class, Disease Type, Route of Administration, Distribution Channel, End User)
  • US
  • Canada
• Europe (Treatment Type, Drug Class, Disease Type, Route of Administration, Distribution Channel, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Drug Class, Disease Type, Route of Administration, Distribution Channel, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Drug Class, Disease Type, Route of Administration, Distribution Channel, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Drug Class, Disease Type, Route of Administration, Distribution Channel, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Mallinckrodt plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Orphan Therapeutics LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Behring LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Octapharma AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kedrion Biopharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biotest AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LFB USA Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio Product Laboratory Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• China Biologic Products Holdings Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ferring Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biopas Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cumberland Pharmaceuticals Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Melinta Therapeutics LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Salix Pharmaceuticals Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations